Veterinary Medicines

Syvazul BTV 3 (--) - Suspension for injection

Authorised
  • Bluetongue virus, serotype 3, strain BTV-3/NET2023, Inactivated
Download as PDF

Product identification

Medicine name:
Syvazul BTV 3 (--) - Suspension for injection
Active substance:
  • Bluetongue virus, serotype 3, strain BTV-3/NET2023, Inactivated
Target species:
  • Sheep
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Bluetongue virus, serotype 3, strain BTV-3/NET2023, Inactivated
    Presentation_strength:≥ 10⁶·⁹ CCID₅₀ Reference:In House Index:0
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Sheep
      • All relevant tissues
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI04AA02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
Package description:
  • Packaging:Vial (PP), Package_size:1 vial, Content:80 ml
  • Packaging:Vial (PP), Package_size:1 vial, Content:200 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • New active substance - Exceptional circumstances (Article 25 of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Laboratorios Syva S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Syva S.A.
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:

Documents

Combined File of all Documents

English (PDF)
Published on: 5/03/2025
Download
Bulgarian (PDF)
Published on: 5/03/2025
Download
Croatian (PDF)
Published on: 5/03/2025
Download
Czech (PDF)
Published on: 5/03/2025
Download
Danish (PDF)
Published on: 5/03/2025
Download
Dutch (PDF)
Published on: 5/03/2025
Download
Estonian (PDF)
Published on: 5/03/2025
Download
Finnish (PDF)
Published on: 5/03/2025
Download
French (PDF)
Published on: 5/03/2025
Download
German (PDF)
Published on: 5/03/2025
Download
Greek (PDF)
Published on: 5/03/2025
Download
Hungarian (PDF)
Published on: 5/03/2025
Download
Icelandic (PDF)
Published on: 5/03/2025
Download
Italian (PDF)
Published on: 5/03/2025
Download
Latvian (PDF)
Published on: 5/03/2025
Download
Lithuanian (PDF)
Published on: 5/03/2025
Download
Maltese (PDF)
Published on: 5/03/2025
Download
Norwegian (PDF)
Published on: 5/03/2025
Download
Polish (PDF)
Published on: 5/03/2025
Download
Portuguese (PDF)
Published on: 5/03/2025
Download
Romanian (PDF)
Published on: 5/03/2025
Download
Slovak (PDF)
Published on: 5/03/2025
Download
Slovenian (PDF)
Published on: 5/03/2025
Download
Spanish (PDF)
Published on: 5/03/2025
Download
Swedish (PDF)
Published on: 5/03/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."